Helix Acquisition Corp. III (Ticker: HLXC US) is a Cayman Islands-incorporated blank check company (SPAC) formed to effect a merger, share exchange, asset acquisition, or similar business combination. The company intends tao focus its search on the healthcare sector, specifically targeting opportunities in biotech, med tech, and life sciences. Helix Acquisition Corp. III plans to list on the NASDAQ on January 23, 2026.

According to pricing reports, the company raised $150 million by offering 15 million Class A ordinary shares at $10.00 per share. This represents an upsized offering from the initially filed 12.5 million shares. Distinguishing itself from many other SPACs, this transaction is a stock-only offering and does not include warrants.

The company is sponsored by Helix Holdings III LLC, an affiliate of healthcare investment firm Cormorant Asset Management, and is led by CEO and Chairperson Bihua Chen. Proceeds from the IPO are reportedly intended to fund the identification and completion of a business combination with a suitable target. Leerink Partners and Oppenheimer & Co. acted as joint bookrunning managers for the deal.